Opinion|Videos|November 6, 2024

Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

Panelists discuss how they approach and potentially adapt the dosing and administration regimens of approved and investigational FcRn inhibitors in their myasthenia gravis patients, considering the prescribed guidelines and individual patient needs.

Video content above is prompted by the following:

  • Approved and investigational FcRn inhibitors have different dosing/administration regimens.
    • Do you follow these dosing regimens in your patients?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME